CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

Data ReadoutpositiveBOND-003Positive

AI Analysis

Summary

CG Oncology published Phase 3 BOND-003 Cohort C study results in The Lancet Oncology, demonstrating durable responses and bladder preservation in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with favorable safety profile.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Publication of Phase 3 BOND-003 Cohort C study results showing durable responses, bladder preservation, low disease progression rate, and favorable safety and tolerability

Importance:7/10

Sentiment:

0.80

Phase 3 databladder canceroncologypublicationpositive results

Related Companies

$CGON

Read the original article

Published by GlobeNewswire Clinical Studies on July 27, 2026 10:45 PM

Read Original